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RESEARCH ARTICLE Open Access
Impact of BCG vaccination on incidence of
tuberculosis disease in southern Ireland
Eileen Sweeney1,5* , Darren Dahly2, Nahed Seddiq1,5, Gerard Corcoran3, Mary Horgan1,4,5 and Corinna Sadlier1,4
Abstract
Background: Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause from a single
infectious agent. Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for TB, yet its efficacy remains debated
with variations in vaccine sub-strains, policies, and practices observed across the world. Three BCG vaccination
policies were implemented across adjoining regions in the South West of Ireland from 1972; neonatal vaccination
(vaccinated Region-A), vaccination of children aged 10–12 years (vaccinated Region-B) and no vaccination (unvaccinated
Region-C). The aim of this study is to examine the impact of different BCG vaccination policies on incidence of TB disease
in the South of Ireland over a 13-year period.
Methods: Cases of active TB disease from 2003 to 2016 were identified through surveillance data. Residential addresses
for each case were geocoded using the Google Maps API. Addresses were linked to 2011 census population data and to
Local Health Offices BCG coverage data for study regions A-C. A steady-state population was assumed to calculate the 13-
year incidence of TB disease. Using SatScan (v9.4.4), spatial clusters were identified at a small area level with the spatial
scan statistic based on the discrete Poisson probability distribution.
Results: Of 621 TB disease cases identified, 510 could be linked to the study area based on the reported addresses. The
median age was 42 years (range 4months - 94 years), 65% male and 66% Irish born. The incidence of TB disease was
higher in the unvaccinated population, region-C 132/100,000 (95% CI 116–150) versus vaccinated region-A 56/100,000
(95%CI 45–69) and region-B 44/100,000 (95%CI 29–63). A spatial cluster analysis identified a single high-risk cluster in
region -C where the relative risk (vs. the areas outside of the cluster) was 4.94 (95% CI 4.03 to 5.96).
Conclusion: Our study demonstrates significant regional variation in the incidence of TB in demographically
similar populations based on BCG vaccination policy. This observation is particularly noteworthy in a country
with low TB disease incidence such as Ireland. These findings strengthen existing data demonstrating efficacy
of BCG vaccination for primary prevention of TB disease.
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Background
Tuberculosis (TB) is the ninth leading cause of death
worldwide and the leading cause from a single infectious
agent. In 2017 the World Health Organisation (WHO) es-
timated that 10 million people were infected with Myco-
bacterium tuberculosis (MTB) and that there had been 1.6
million TB related deaths [1]. The discovery of the Bacille
Camille-Guerin (BCG) vaccine in the 1920s was a
milestone in TB control. In 1949 BCG vaccine was intro-
duced in Ireland by Dr. Dorothy Stopford Price [2].
Indication for and efficacy of BCG vaccine remains de-
bated with variations in vaccine sub-strains, policies, and
practices observed across the world [3]. The BCG vaccine
has been subject to several trials which have estimated an
overall protective efficacy of 60–80% against severe forms
of TB disease in children, particularly meningitis [4]. Pro-
tection against pulmonary TB varies according to age of ad-
ministration of BCG vaccine and geographical location. By
the 1970s, pilot studies in Western Europe demonstrated a
decline in risk of serious forms of TB in children [5].
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Data also indicated a protective effect of BCG vaccine
in adults, nevertheless, failure to impact the global inci-
dence of TB resulted in a discontinuation of BCG vac-
cination programmes in several countries including
former Czechoslovakia (1961–1972) and Sweden (1975)
[6].
In Ireland, universal neonatal BCG vaccination was in-
troduced in the 1950’s. The vaccine was discontinued in
a region in the South of Ireland (Cork) in 1972 based on
low incidence of TB disease in the area and concerns re-
garding interpretation of positive Mantoux tests in the
immunised population potentially complicating future
diagnosis of TB disease [2]. Elsewhere in Ireland, a uni-
versal BCG vaccination policy remained in place as evi-
dence continued to support its use in the broader Irish
context [7].
BCG vaccination policy in Ireland was reviewed in ac-
cordance with other European countries in 2014 [8, 9].
Universal BCG vaccination was discontinued in 2015 as
a result of the global BCG vaccine shortage and is no
longer recommended in national immunisation guide-
lines in Ireland as of 2016 [10].
In this study, we analyse TB surveillance data in the South
of Ireland over a thirteen-year period (2003–2016). This data
is unique in that in compares three different BCG vaccin-
ation policies across bordering geographical regions, neo-
natal vaccination (Region-A), vaccination of children aged
10–12 years (Region-B) and no vaccination (unvaccinated,
Region-C).
Aim
The aim of this study is to examine the impact of three
different BCG vaccination policies on observed inci-
dence of TB disease in the South of Ireland over a
13-year period.
Data collection
All cases of suspected TB disease, whether in the commu-
nity or hospital setting, have isolates taken that are sent to
the regional TB laboratory. Surveillance data from the re-
gional TB laboratory was used to identify all MTB culture
isolates from 2003 to 2016. Data were collected over a
13-year period (08/2003 to 12/2016) for all reported cul-
tured cases of MTB.
Cases were divided by Local Health Offices (LHO) region
within the South of Ireland (North Lee, South Lee, West
Cork, North Cork and Kerry). National crude incidence rates
were compared with Health Service Executive (HSE) South
rates using census 2011 population data in keeping with
HPSC (Health Protection Surveillance Centre) reports [11].
Ethical approval was granted through the Research
Ethics Committee of the Cork Teaching Hospitals.
Methods
Study design and population
All cases included in our study were exclusively active
TB disease. Isolates on all suspected cases of active
TB disease within the study area are routinely sent to
Cork University Hospital for culturing and identifica-
tion. The study preceded the availability of conven-
tional molecular methods for identification of TB
disease, thus all cases were identified through growth
on culture media.
Residential addresses for each TB case were geo-
coded using the Google Maps API. Information about
case locations were spatially linked to 2011 census
population data [12] at the small area level using
QGIS (v 2.18.13). Spatial data were similarly linked to
the coverage of the HSE LHO for Kerry, West Cork,
South Lee, North Lee, and North Cork. The 13-year
incidence of TB disease was calculated assuming a
steady-state population. Using SatScan (v 9.4.4), we
identified spatial clusters of higher than normal TB
disease incidence at the small area level with the
spatial scan statistic based on the discrete Poisson
probability distribution.
Exclusion criteria
All cases of non-tuberculosis mycobacterium or any case
of MTB cultured in the regional TB lab but not located
in our study area were excluded.
Results
A total of 621 cases of TB disease were identified
during the study period. The median age was 42 years
(range 4 months - 94 years; 95% of the sample were
older than 18 years of age). The addresses of 577
(93%) cases were successfully geocoded. We excluded
67 cases for linking to addresses outside the coverage
area, thus 510 (80%) cases were included in further
analysis. 327 (65%) cases were male, 339 (66%) of
Irish origin. 398 (78%) cases were pulmonary tubercu-
losis 104 (20%) cases were extra pulmonary.
The incidence of TB disease in Region-A (neonatal
vaccination programme in a rural area) was 56/
100,000 (95% confidence interval, 95% CI, 45–69).
The incidence of TB disease in Region-B (childhood
vaccination programme in a rural area) was 44/
100,000 (95% CI, 29–63). The incidence of TB disease
in Region-C (unvaccinated population in an urban
area) was 132/100,000 (95% CI, 116–150) (Fig. 1).
Within the unvaccinated population (Region-C), 65%
of TB cases were Irish born compared to 72% in the vac-
cinated population (Table 1).
A spatial cluster analysis identified a single
high-risk cluster in Cork City (unvaccinated popula-
tion in Region -C). The cluster included 138 cases in
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a population of 46,000, and the relative risk (vs. the
areas outside of the cluster) was 4.94 (95% CI 4.03 to
5.96) (Additional file 1.).
The year-on-year incidence in the 20 to 35-year-old
age range does not decrease as one would expect, but
this is due to the small number of cases in region A and
B. (Fig. 2).
Limitations
This study has a number of limitations. The unvaccinated
population in Region-C represents an urban area. While
population density was accounted for, deprivation index was
not. This needs to be considered as a potential confounding
factor, as homelessness and lower socioeconomic classes are
traditionally considered greater issues in urban areas.
Fig. 1 Incidence of Tuberculosis Disease in Southern Ireland per 100,000 [95% CI] from 2003 to 2016. a (neonatal vaccination programme in a
rural area). b (childhood vaccination programme in a rural area). c (unvaccinated population in an urban area). Abbreviations: CI Confidence
Interval. Attribution: Dr. Darren Dahly, Principal Statistician, Cork University Hospital
Table 1 Demographics of Tuberculosis Disease cases in Southern Ireland, 2003–2016
TB Disease Region A * Region B** Region C *** Total
Kerry West Cork North Cork North Lee South Lee
Number of Cases / 100,000 66 (13%) 20 (4%) 54 (10.5%) 193 (38%) 177 (34.5%) 510
Median age @ dx 44.5 61.5 43.5 39 39 42
Age </= 18 3 0 2 13 13 31
Age range 0-92 yrs 20-85 yrs 2-89 yrs 0-90 yrs 0-93 yrs 0-93 yrs
Male 44 10 30 131 117 332
Female 22 10 24 59 59 174
Unknown 0 0 0 3 1 4
HIV 1 0 2 2 9 14
Irish born 49 13 39 124 114 339
Foreign 12 6 8 41 34 101
Unknown 5 1 7 28 29 70
MDR 0 0 1 2 1 4
*Neonatal vaccination policy, ** Vaccinated at 12–13 years ***Unvaccinated
Unknown indicates where data was unavailable.
Abbreviations: MDR Multi Drug Resistant
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Population rather than individual BCG vaccination
coverage estimates were used. Uptake of vaccines in the
different policy areas was not represented in the data. It
was reported that several children where there was no
BCG vaccination available (Region-C) received the BCG
vaccine in other jurisdictions due to parental concern
following local outbreaks.
The small number of cases, and sample size make it
more difficult to detect any substantial decrease in the
incidence rate over time, particularly when attempting
to focus on a specific age group i.e. the 25–35-year olds.
Finally, the study period began after implementation of
the differing vaccine policies and thus it is not possible to
directly assess the effect of each policy on each region.
Strengths
In this study we observe the impact of different BCG
policies on a defined geographic region over time. Al-
though this is widely studied across different resource
settings and countries, to our knowledge this has not
been studied on populations with such comparable
demographics in a low TB disease incidence country.
Discussion
Prevention and treatment of TB remains a significant chal-
lenge worldwide. In 2017, the WHO estimated that 23% of
the world’s population have latent TB infection (LTBI) and
that there had been 1.6 million TB disease related deaths [1].
In Ireland in 2017 the crude national incidence rate of TB
disease was 6.7/100,000; however there is little information
in relation to the prevalence of LTBI in Ireland [13].
National data from the HPSC shows that the incidence
of TB disease in Southern Ireland during the study
period was consistently above that of the general Irish
population [11]. We postulate that this is as a result of
the variation in regional BCG vaccine policy.
Presently, there are three health interventions available
for TB prevention; screening and proactive treatment of
LTBI, transmission prevention through infection control
and targeted vaccination of at-risk groups with the BCG
vaccine.
BCG vaccine is no longer recommended in the general
population in low incidence countries including Ireland
as its use is not supported by risk-benefit or cost effect-
iveness analysis [14, 15]. In low incidence countries pre-
vention strategies focus on screening at-risk groups and
chemoprophylaxis with BCG vaccine targeted to specific
at-risk populations. BCG vaccination programmes con-
tinue in high incidence countries.
Conclusion
Our study demonstrates significant regional variation in
the incidence of TB in demographically similar popula-
tions based on BCG vaccination policy. This observation
is particularly noteworthy in a country with low TB dis-
ease incidence such as Ireland. These findings
strengthen existing data demonstrating efficacy of BCG
vaccination for primary prevention of TB disease.
Fig. 2 Distribution of Tuberculosis Disease cases in Southern Ireland over Time Numbers plotted: Incidence of TB disease per 100,000 [95% CI]
Abbreviations: HSE Health Service Executive, LHO Local Health Office Attribution: Dr. Darren Dahly, Principal Statistician, Cork University Hospital.
Incidence of Tuberculosis Disease in Southern Ireland per 100,000 [95% CI] from 2003 to 2016)
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Additional file
Additional file 1: Cluster of 138 cases of Tuberculosis Disease in
unvaccinated population Numbers plotted: Relative risk compared to the
area outside the cluster [95% CI]. 138 cases in a population of 46,000 were
identified by spatial cluster analysis of all cases identified throughout the
study period. Abbreviations: RR Relative Risk. Attribution: Dr. Darren Dahly,
Principal Statistician, Cork University Hospital. (PNG 1120 kb)
Abbreviations
BCG: Bacille Camille-Guerin; HPSC: Health Protection Surveillance Centre;
HSE: Health Service Executive; LHO: Local Health Offices; LTBI: Latent TB
infection; MTB: Mycobacterium tuberculosis; TB: Tuberculosis; WHO: World
Health Organisation
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